TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cynata Therapeutics Limited ( (AU:CYP) ).
Cynata Therapeutics Limited announced an investor webinar hosted by CEO Dr. Kilian Kelly, aimed at updating shareholders on the company’s progress and future plans. This event underscores Cynata’s ongoing commitment to transparency and stakeholder engagement as it advances its clinical trials and explores the potential of its Cymerus™ technology in treating a wide range of diseases.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company that specializes in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform technology, which utilizes induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) at a commercial scale. This approach addresses the challenges of conventional MSC production by eliminating the need for multiple donor tissues and reducing product inconsistency. Cynata has shown positive results in Phase 1 clinical trials for conditions like steroid-resistant acute graft versus host disease and diabetic foot ulcers, and is conducting further trials in various other diseases.
YTD Price Performance: -29.17%
Average Trading Volume: 182,984
Technical Sentiment Signal: Sell
Current Market Cap: A$38.41M
Learn more about CYP stock on TipRanks’ Stock Analysis page.